Andrew Strahs

6.9k citations

52 papers · 2.8k indexed · 2 hit papers · h-index 20

Impact in

Cancer Research top 2%
- Cancer Genomics and Diagnostics
Pulmonary and Respiratory Medicine top 2%
- Renal cell carcinoma treatment
- Advanced Breast Cancer Therapies

Papers in

Cancer Research 21
- Cancer Genomics and Diagnostics 19
Pulmonary and Respiratory Medicine 34
- Renal cell carcinoma treatment 25
- Lung Cancer Treatments and Mutations 5

Co-authors: Anna Berkenblit Mary Sara McPeek Jay Feingold Laurence Moore Cezary Szczylik Janice P. Dutcher Akshay Vaishnaw Amy Simon
Journals: Journal of Clinical Oncology (19 papers)European Journal of Cancer (3 papers)Breast Cancer Research and Treatment (2 papers)Cancer Research (2 papers)Blood (2 papers)
Partner nations: United States Poland Russia

In The Last Decade

Andrew Strahs

52 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 2016 · 586 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 New England Journal of Medicine
2009 Journal of Clinical Oncology

Peers

Countries citing papers authored by Andrew Strahs

Since Specialization

Citations

This map shows the geographic impact of Andrew Strahs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Strahs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Strahs more than expected).

Fields of papers citing papers by Andrew Strahs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Strahs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Strahs. The network helps show where Andrew Strahs may publish in the future.

Co-authors

The 25 scholars most cited alongside Andrew Strahs, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Strahs Line = papers co-authored together Andrew Strahs links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 New England Journal of Medicine ·Kevin Fitzgerald, Suellen White, Anna Borodovsky, Brian R. Bettencourt, Andrew Strahs, Valerie A. Clausen, Peter Wijngaard, Jay D. Horton, Jörg Täubel, Ashley Brooks, Chamikara Fernando, Robert S. Kauffman, David Kallend, Akshay Vaishnaw, Amy Simon Hit paper breakdown →	2016	586
2	A Phase Ib Study of the VEGF Receptor Tyrosine Kinase Inhibitor Tivozanib and Modified FOLFOX-6 in Patients With Advanced Gastrointestinal Malignancies Clinical Colorectal Cancer ·Corina N.A.M. Oldenhuis, Walter J. Loos, Brooke Esteves, Leni van Doorn, Monette Cotreau, Andrew Strahs, Martha W. den Hollander, Jourik A. Gietema, Elisabeth G.E. de Vries, Ferry A.L.M. Eskens	2014	8
3	Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor Clinical Pharmacology in Drug Development ·Monette Cotreau, Nicholas Siebers, James D. Miller, Andrew Strahs, William J. Slichenmyer	2014	18
4	Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma European Journal of Cancer ·Mayer Fishman, S. Srinivas, Ralph J. Hauke, R. J. Amato, B. Esteves, Monette Cotreau, Andrew Strahs, William J. Slichenmyer, Pankaj Bhargava, Fairooz F. Kabbinavar	2013	25
5	A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer Breast Cancer Research and Treatment ·Erica L. Mayer, M. E. Scheulen, Joshua A. Beckman, Heike Richly, Amanda Duarte, Monette Cotreau, Andrew Strahs, Shefali Agarwal, Linda S. Steelman, Eric P. Winer, Maura N. Dickler	2013	21
6	Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Journal of Clinical Oncology ·Antonio C. Wolff, Ann Lazar, Igor Bondarenko, August Garin, Stephen Brincat, Louis W.C. Chow, Yan Sun, Zora Nešković‐Konstantinović, Rodrigo C. Guimarães, P. Fumoleau, Arlene Chan, Soulef Hachemi, Andrew Strahs, Maria Cincotta, Anna Berkenblit, Mizue Krygowski, Lih Lisa Kang, Laurence Moore, Daniel F. Hayes	2012	222
7	Absorption, Metabolism, and Excretion of [¹⁴C]‐Tivozanib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Male Participants: A Phase I, Open‐Label, Mass‐Balance Study Clinical Pharmacology in Drug Development ·Monette Cotreau, Christine Hale, Lindsey Jacobson, Claudine S. Oelke, Andrew Strahs, R. G. Kochan, Madhu Sanga, William J. Slichenmyer, Dennis Vargo	2012	11
8	Abstract 752: The effect of food on the pharmacokinetics of tivozanib Cancer Research ·Monette Cotreau, T. Alex King, Lisa Massmanian, Andrew Strahs, William J. Slichenmyer, Dennis Vargo	2012	3
9	Final results of a phase Ib study of tivozanib and FOLFOX6 in patients (pts) with advanced gastrointestinal (GI) tumors. Journal of Clinical Oncology ·Ferry A.L.M. Eskens, Corina N.A.M. Oldenhuis, Walter J. Loos, Brooke Esteves, Leni van Doorn, Monette Cotreau, Pankaj Bhargava, Joshua Zhang, Andrew Strahs, Martha W. den Hollander, Jourik A. Gietema	2012	3
10	596 The Effect of Rifampin On the Pharmacokinetics of Tivozanib, a Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor European Journal of Cancer ·Monette Cotreau, D. Subic, Lisa Massmanian, Andrew Strahs, Dennis Vargo	2012	2
11	Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma PharmacoEconomics ·Arthur S. Zbrozek, Gary R. Hudes, Donna E. Levy, Andrew Strahs, Anna Berkenblit, Robert De Marinis, Shreekant Parasuraman	2010	28
12	Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy Breast Cancer Research and Treatment ·Christina Coughlin, Daniel St Johnston, Andrew Strahs, Michael E. Burczynski, Sarah Bacus, Jason E. Hill, Jay Feingold, Charles Zacharchuk, Anna Berkenblit	2010	26
13	Analysis of PTEN and HIF‐1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon‐α Cancer ·Robert A. Figlin, Paul de Souza, David F. McDermott, Janice P. Dutcher, Anna Berkenblit, Alexandra Thiele, Mizue Krygowski, Andrew Strahs, Jay Feingold, Joseph Boni, Gary R. Hudes	2009	67
14	Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies Medical Oncology ·Janice P. Dutcher, Paul de Souza, David F. McDermott, Robert A. Figlin, Anna Berkenblit, Alexandra Thiele, Mizue Krygowski, Andrew Strahs, Jay Feingold, Gary R. Hudes	2009	194
15	Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features Annals of Oncology ·Joaquim Bellmunt, Cezary Szczylik, Jay Feingold, Andrew Strahs, Anna Berkenblit	2008	129
16	A study of 17β-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy Maturitas ·Monette Cotreau, Vargheese M. Chennathukuzhi, Heather A. Harris, Lixin Han, Andrew J. Dorner, Glen Apseloff, Usha Varadarajan, Ellyn Hatstat, Marjorie Zakaria, Andrew Strahs, Judy S. Crabtree, Richard C. Winneker, Scott A. Jelinsky	2007	34
17	Molecular Classification of Crohn's Disease and Ulcerative Colitis Patients Using Transcriptional Profiles in Peripheral Blood Mononuclear Cells Journal of Molecular Diagnostics ·Michael E. Burczynski, Ron Peterson, Natalie C. Twine, Krystyna Zuberek, Brendan J. Brodeur, Lori Casciotti, Vasu Maganti, Padma Reddy, Andrew Strahs, Fred Immermann, Walter Spinelli, Ulrich Schwertschlag, Anna M. Slager, Monette Cotreau, Andrew J. Dorner	2006	191
18	A Single Administration of Recombinant Human Interleukin‐12 Is Associated With Increased Expression Levels of Interferon‐gamma and Signal Transducer and Activator of Transcription in Healthy Subjects The Journal of Clinical Pharmacology ·Caroline Trudeau, Monette Cotreau, Lucille Stonis, Kevin Dykstra, Judy Oestreicher, Andrew Strahs, Andrew J. Dorner, Victor H. Van Cleave, William L. Trepicchio, Ullrich Schwertschlag	2005	5
19	A multiple‐dose, safety, tolerability, pharmacokinetics and pharmacodynamic study of oral recombinant human interleukin‐11 (oprelvekin) Biopharmaceutics & Drug Disposition ·Monette Cotreau, Lucille Stonis, Andrew Strahs, Ullrich Schwertschlag	2004	9
20	Assessment of Linkage Disequilibrium by the Decay of Haplotype Sharing, with Application to Fine-Scale Genetic Mapping The American Journal of Human Genetics ·Mary Sara McPeek, Andrew Strahs	1999	167

About Andrew Strahs

Andrew Strahs is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Nephrology, Oncology and Hematology, having authored 52 papers that have together received 2.8k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (25 papers), Cancer Genomics and Diagnostics (19 papers), Renal and related cancers (12 papers), Cancer Treatment and Pharmacology (6 papers), PI3K/AKT/mTOR signaling in cancer (6 papers), Economic and Financial Impacts of Cancer (5 papers), HER2/EGFR in Cancer Research (5 papers) and Lung Cancer Treatments and Mutations (5 papers). The work is most often cited by research in Cancer Research (750 citations), Pulmonary and Respiratory Medicine (1.0k citations), Genetics (323 citations), Oncology (651 citations) and Molecular Biology (1.6k citations). Andrew Strahs has collaborated with scholars based in United States, Poland and Russia. Frequent co-authors include Anna Berkenblit, Mary Sara McPeek, Jay Feingold, Laurence Moore, Cezary Szczylik, Janice P. Dutcher, Akshay Vaishnaw, Amy Simon, Peter Wijngaard and Ashley Brooks. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Breast Cancer Research and Treatment, Cancer Research and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact